Literature DB >> 21742527

Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations.

Jae Hyuk Choi1, Barbara Stubblefield, Mark R Cookson, Ehud Goldin, Arash Velayati, Nahid Tayebi, Ellen Sidransky.   

Abstract

Recent studies show an increased frequency of mutations in the glucocerebrosidase gene (GBA1) in patients with α-synucleinopathies including Parkinson disease. Some patients with Gaucher disease (GD) develop parkinsonism with α-synuclein-positive inclusions post mortem. Proteins were extracted from the cerebral cortex of subjects with synucleinopathies with and without GBA1 mutations, controls and patients with GD. Patients with GBA1-associated synucleinopathies showed aggregation of oligomeric forms of α-synuclein in the SDS-soluble fraction, while only monomeric forms of α-synuclein were seen in subjects with GBA1 mutations without parkinsonism. Thus, brains from patients with GBA1-associated parkinsonism show biochemical characteristics typical of Lewy body disorders. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742527      PMCID: PMC3352315          DOI: 10.1016/j.ymgme.2011.06.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  18 in total

Review 1.  Parkinson's disease.

Authors:  Ali Samii; John G Nutt; Bruce R Ransom
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  The E326K mutation and Gaucher disease: mutation or polymorphism?

Authors:  J K Park; N Tayebi; B K Stubblefield; M E LaMarca; J J MacKenzie; D L Stone; E Sidransky
Journal:  Clin Genet       Date:  2002-01       Impact factor: 4.438

Review 4.  Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.

Authors:  D L Stone; N Tayebi; E Orvisky; B Stubblefield; V Madike; E Sidransky
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

5.  Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.

Authors:  Ozlem Goker-Alpan; Barbara K Stubblefield; Benoit I Giasson; Ellen Sidransky
Journal:  Acta Neuropathol       Date:  2010-09-14       Impact factor: 17.088

6.  Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.

Authors:  Suzanne Lesage; Mathieu Anheim; Christel Condroyer; Pierre Pollak; Franck Durif; Céline Dupuits; François Viallet; Ebba Lohmann; Jean-Christophe Corvol; Aurélie Honoré; Sophie Rivaud; Marie Vidailhet; Alexandra Dürr; Alexis Brice
Journal:  Hum Mol Genet       Date:  2010-10-14       Impact factor: 6.150

7.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

8.  Glucocerebrosidase mutations in subjects with parkinsonism.

Authors:  Alicia Lwin; Eduard Orvisky; Ozlem Goker-Alpan; Mary E LaMarca; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

Review 9.  Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies.

Authors:  Marina D Kirkitadze; Gal Bitan; David B Teplow
Journal:  J Neurosci Res       Date:  2002-09-01       Impact factor: 4.164

10.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

View more
  35 in total

1.  Mechanisms of Gaucher disease pathogenesis.

Authors:  Simon Wheeler; Dan John Sillence
Journal:  Ann Transl Med       Date:  2015-05

2.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

Review 3.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

4.  Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.

Authors:  Nahid Tayebi; Loukia Parisiadou; Bahafta Berhe; Ashley N Gonzalez; Jenny Serra-Vinardell; Raphael J Tamargo; Emerson Maniwang; Zachary Sorrentino; Hideji Fujiwara; Richard J Grey; Shahzeb Hassan; Yotam N Blech-Hermoni; Chuyu Chen; Ryan McGlinchey; Chrissy Makariou-Pikis; Mieu Brooks; Edward I Ginns; Daniel S Ory; Benoit I Giasson; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2017-11-21       Impact factor: 4.797

5.  GBA mutations in Parkinson disease: earlier death but similar neuropathological features.

Authors:  C H Adler; T G Beach; H A Shill; J N Caviness; E Driver-Dunckley; M N Sabbagh; A Patel; L I Sue; G Serrano; S A Jacobson; K Davis; C M Belden; B N Dugger; S A Paciga; A R Winslow; W D Hirst; J G Hentz
Journal:  Eur J Neurol       Date:  2017-08-17       Impact factor: 6.089

6.  Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.

Authors:  Thai Leong Yap; Zhiping Jiang; Frank Heinrich; James M Gruschus; Candace M Pfefferkorn; Marilia Barros; Joseph E Curtis; Ellen Sidransky; Jennifer C Lee
Journal:  J Biol Chem       Date:  2014-11-26       Impact factor: 5.157

7.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

Review 8.  The link between the GBA gene and parkinsonism.

Authors:  Ellen Sidransky; Grisel Lopez
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

9.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

Review 10.  The association between ß-glucocerebrosidase mutations and parkinsonism.

Authors:  Matthew Swan; Rachel Saunders-Pullman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.